{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.6","upperLimit":"45.2","value":"33.8"}]}],"title":"MRD negative CR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"15.6","value":"7.5"}]}],"title":"MRD positive CR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"The MRD status by blinded independent review refers specifically to results of central pathologist read of bone marrow biopsy by immunohistochemistry.\n\nThe CR with Positive or Negative MRD requires all of the following to be present:\n\n* No evidence of leukemic cells in the peripheral blood and/or by routine H/E staining of bone marrow. Minimal Residual Disease: CR with HCL evident in blood or in bone marrow biopsy by immunohistochemistry.\n* Resolution of any hepatomegaly, splenomegaly, and abnormal (\\>= 2 cm minimum length) lymphadenopathy by CT or MRI. Although a normal spleen size is not defined, the maximum diameter of the spleen should be either \\< 17 cm or have decreased by \\>25% from its baseline.\n* Normal CBC as exhibited by: Neutrophils \\>= 1.5 x 10\\^9/L, Platelets \\>= 100 x 10\\^9/L, and hemoglobin \\>= 11.0 g/dL without transfusions or growth factors for at least 4 weeks.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous infusion of moxetumomab pasudotox 40 µg/kg on Days 1, 3, and 5 of each 28-day cycle for up to 6 cycles, until documentation of complete response, progressive disease, initiation of alternate therapy, or unacceptable toxicity.","id":"OG000","title":"Moxetumomab Pasudotox 40 µg/kg"}],"paramType":"NUMBER","populationDescription":"The ITT population included participants who entered into the study and treated with moxetumomab pasudotox.","reportingStatus":"POSTED","timeFrame":"Prior to each treatment cycle, EOT (up to 24 weeks), monthly from the EOT assessment until the Day 181 assessment (only for CBC), at follow-up visits every 3 months for the next 24 months, and every 6 months thereafter (approximately 6 years)","title":"Percentage of Participants With Minimal Residual Disease (MRD) Positive or MRD Negative CR Assessed by Blinded Independent Central Review","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}